COMMUNIQUÉS West-GlobeNewswire

The Ensign Group Announces Expansion Into Florida
02/10/2026
SAN JUAN CAPISTRANO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
The Ensign Group Adds Operations in Washington
02/10/2026
SAN JUAN CAPISTRANO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior living [...]
The Ensign Group Adds New Operations in Colorado
02/10/2026
SAN JUAN CAPISTRANO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
Digbi Health Unifies Metabolic, Inflammatory and Hormonal Care on One Precision Biology Telehealth Platform
02/10/2026
Employers can now deliver GLP-1 and hormone replacement therapy through a unified care team, without layering on another standalone point solution MOUNTAIN VIEW, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Digbi Health [...]
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
02/10/2026
BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS or the “Company”), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it [...]
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)- [...]
Cartesian Therapeutics Announces New Employment Inducement Grants
02/10/2026
FREDERICK, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced [...]
Walden Biosciences to Present Phase 1+ and Phase 2 Data for WAL0921 at American Society of Nephrology Kidney Week
02/10/2026
Late-breaking poster presentation to showcase initial activity of WAL0921 in proteinuric kidney disease Additional poster demonstrates WAL0921 is safe, well tolerated, and reduces circulating suPAR levels in healthy [...]
Published Human Research Gives Family Caregivers a Way to Evaluate Joint Supplements
02/10/2026
Three published human studies of the complete Cartigenix HP formulation offer the kind of named, verifiable evidence a caregiver can bring to a family member's clinician Scottsdale, AZ, Oct. 02, 2026 (GLOBE NEWSWIRE [...]
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
CLEVELAND, Ohio, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were [...]
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on October 1 [...]
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
02/10/2026
Jena, Germany, Oct. 02, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company [...]
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
02/10/2026
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations, including two Late Breaking Clinical Research presentations and two [...]
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it [...]
Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)
02/10/2026
BASEL, Switzerland, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Today Ultragenyx announced that the European Medicines Agency (EMA) has validated the Company's Marketing Authorisation Application (MAA) for its investigational [...]
Addex Therapeutics Announces Executive Management Changes
02/10/2026
Jean-Philippe Rocher Appointed Head of Pharmaceutical Development Mikhail Kalinichev, Head of Translational Science, Steps Down Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 2, 2026 - Addex [...]
Ending MS Is Within Reach: National MS Society Raises a Record-Breaking $12 Million to Launch the Campaign to End MS
02/10/2026
Nearly 500 guests gathered at Cipriani 42nd Street for the Campaign to End MS Gala, emceed by Ginger Zee and honoring David Osmond and his family, as the Society kicked off its five-year, $1 billion campaign NEW YORK, [...]
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
01/10/2026
ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now live WOBURN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Replimune Group [...]
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
01/10/2026
NEW HAVEN, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that novel [...]

Pages